23 April 2026 – Minneapolis, MN – Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the U.S. commercial launch of its NorthStar® Mapping System. As the first and only cardiac mapping and guidance system designed specifically to harness the power of magnetic resonance (MR) imaging to see the heart throughout a minimally-invasive interventional procedure, NorthStar brings the … Read More

12 January 2026 – Minneapolis, MN, Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s Vision-MR® Diagnostic Catheter under the premarket notification process. This marks the Company’s first FDA clearance. The Vision-MR Diagnostic catheter is designed to be used under … Read More

The upcoming episode of Now We Know! with Steve Guttenberg, aired Saturday, December 13 on CNBC, viewers will be introduced to Imricor, a pioneer in MRI-guided cardiac ablation technology. The Now We Know! crew visited Imricor’s headquarters in Minneapolis, Minnesota, to learn how the company is advancing electrophysiology with real-time MRI imaging. The segment also features insights from physicians at … Read More

4 November 2025 – Minneapolis, MN, Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. Amsterdam UMC team, shown here, performed the VT ablation procedure following previous … Read More

18 June 2025 – Minneapolis, MN– Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that the Vision-MR Ablation Catheter 2.0 and Vision-MR Diagnostic Catheter are commercially available for clinical use across Europe. Designed for use in interventional cardiac MRI (iCMR) environments, the Vision-MR Ablation Catheter 2.0 features a range of physician-driven enhancements, including two curve … Read More

8 May 2025 – Minneapolis, MN– Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that the first procedures were performed at Semmelweis University’s Heart and Vascular Centre (Semmelweis), in Budapest, Hungary. Semmelweis performed their first atrial flutter ablations guided by real-time MRI using Imricor’s platform of devices, including the NorthStar® Mapping System, making them the … Read More

16 April 2025 –Minneapolis, MN – Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that it has commenced the VISABL-VT clinical trial by completing the first-in-human ventricular ablation guided by real-time MRI with the Company’s NorthStar Mapping System. The procedure was performed by the team at the Amsterdam University Medical Centre (AUMC), ranked in 2025 … Read More

14 August 2024 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the first real-time iCMR-guided cardiac ablation procedure has been performed in the United States to support the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE … Read More

21 June 2024 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr). … Read More